ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Cymbalta (duloxetine) — U.S. revenue [legacy] by Year
Cymbalta (duloxetine) — U.S. revenue ($M) [legacy] ($M)
Eli Lilly Cymbalta (duloxetine) — U.S. revenue [legacy]: $33.7M in FY2022, down 12.9% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2022
33.7
Period ended Dec 31, 2022
Change on a year earlier
-12.9%
38.7 in FY2021
History
7 years
Since FY2016
Sources
5
Documents cited below
Where the FY2022 figure comes from
Source: Form 10-K (filed 2023-02-22) ↗
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cymbalta (duloxetine) — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 33.7 | -12.9% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 38.7 | -8.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 42.1 | -15.1% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 49.6 | -8.7% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 54.3 | -52.7% | Form 10-K (filed 2021-02-17) ↗ |
| FY2017 | Dec 31, 2017 | 115 | -57.3% | Form 10-K (filed 2020-02-19) ↗ |
| FY2016 | Dec 31, 2016 | 269 | – | Form 10-K (filed 2019-02-19) ↗ |
Cite this data
StockData. (2026). Eli Lilly Cymbalta (duloxetine) — U.S. revenue [legacy] ($M), annual FY2016–FY2022 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-cymbalta-us
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.